|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-4-16
|
|
pubmed:abstractText |
Recombinant factor VIIa (rFVIIa) is used for treatment of bleeding episodes in hemophilia patients who develop inhibitors to factors VIII and IX. We tested the hypothesis that administration of rFVIIa early after injury would decrease bleeding and improve survival after experimental hepatic trauma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0022-5282
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
703-7
|
|
pubmed:dateRevised |
2003-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11956387-Animals,
pubmed-meshheading:11956387-Blood Pressure,
pubmed-meshheading:11956387-Factor VIIa,
pubmed-meshheading:11956387-Liver,
pubmed-meshheading:11956387-Pilot Projects,
pubmed-meshheading:11956387-Prothrombin Time,
pubmed-meshheading:11956387-Random Allocation,
pubmed-meshheading:11956387-Recombinant Proteins,
pubmed-meshheading:11956387-Shock, Hemorrhagic,
pubmed-meshheading:11956387-Swine,
pubmed-meshheading:11956387-Time Factors
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Early use of recombinant factor VIIa improves mean arterial pressure and may potentially decrease mortality in experimental hemorrhagic shock: a pilot study.
|
|
pubmed:affiliation |
Division of Trauma and Surgical Critical Care, University of Miami School of Medicine, Miami, Florida 33101, USA.
|
|
pubmed:publicationType |
Journal Article
|
